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Introduction
Type 2 diabetes is a chronic metabolic disorder, characterised by continuous deterioration in β-cell function and insulin 
resistance that eventually results in poor glycaemic control.1 
When optimal overall glycaemic control cannot be obtained 
over a longer time period, the risk of developing microvascular 
(neuropathy, retinopathy and nephropathy) and macrovascular 
(coronary heart disease, stroke and peripheral vascular disease) 
complications is increased.2,3 To achieve and maintain long-term, 
near-normal glycaemic control, thereby reducing the risk of 
developing late diabetic complications, is to successfully manage 
type 2 diabetes.
Usually, treatment for type 2 diabetes starts with diet and 
exercise. If good glycaemic control is not attained with lifestyle 
changes, treatment with oral antidiabetic drugs (OADs) is 
prescribed. In many cases, existing therapies eventually fail to 
maintain a long-term satisfactory glycaemic control due to the 
continuous decline in β-cell function. Therefore, as the diabetes 
progresses and the OAD therapies no longer sustain good 
glycaemic control, additional treatments (such as insulin) are 
often required.4 In patients treated with insulin secretagogues 
and/or insulin, good glycaemic control can be achieved, but it is 
often at the expense of increased risk of hypoglycaemic episodes 
and weight gain.1,5 Hence, there are unmet medical needs for 
developing new treatments for type 2 diabetes.
Development of the Liraglutide Molecule 
and its Pharmacokinetics
GLP-1 is an incretin hormone secreted from the L cells of 
the intestine and has been considered as a new and promising 
treatment for type 2 diabetes since its discovery in 1984.6 Native 
GLP-1 stimulates endogenous insulin secretion when plasma 
glucose levels are elevated and decreases glucagon secretion.7 
It also decreases gastric motility, which delays gastric emptying 
and leads to reduced appetite and food intake.8 The combination 
of these mechanisms makes GLP-1 a potent blood glucose–
lowering agent and an attractive pharmacological treatment 
for type 2 diabetes.
However, the endogenous GLP-1 has a short half-life 
(1.5-2.1 min), and therefore has limited use as a pharmaceutical 
treatment. The fast elimination of the hormone is mainly due 
to a fast degradation by dipeptidyl peptidase-4 (DPP-4) and 
rapid kidney clearance.6 Thus, treatment strategies have been 
developed in order to overcome the limitation with native GLP-1 
and to develop it further for its full therapeutic potential.
Liraglutide is a human GLP-1 analogue with 97% amino acid 
homology to endogenous GLP-1. The structure of the native 
30-amino acid peptide GLP-1 hormone has been modified in 
order to develop a compound with pharmacokinetic properties 
(tmax of 9–13 h and a t½ of 13 h) appropriate for once-daily 
injection. These modifications include: 1) a C16 fatty (palmitic) 
acid chain that has been attached to the position 26 (lysine) via 
a glutamoyl spacer, and 2) lysine at position 34 that has been 
replaced by arginine.6
Liraglutide is administered as an isotonic solution by 
subcutaneous injection. The protracted pharmacokinetic profile 
of liraglutide is due to a combination of delayed absorption from 
the injection site, albumin binding (98-99%) in the bloodstream 
and the decreased susceptibility to degradation by DPP-4.9
Pre-clinical Studies
GLP-1 affects the β-cell mass through several mechanisms: 
stimulation of β-cell proliferation, promotion of neogenesis and 
inhibition of apoptosis.10
Bregenholt et al. demonstrated that liraglutide protected rat 
β-cells from both cytokine- and free fatty acid (FFA)–mediated 
apoptosis in vitro, under conditions that mimic the pathological 
mechanisms associated with the natural history of type 2 
diabetes.11
Pre-clinical studies in animal models demonstrated that 
liraglutide stimulated β-cell prolifer ation, promoted neogenesis 
and inhibited apoptosis through several mechanisms.10,12,13 
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Abstract
Good glycaemic control in type 2 diabetes can be achieved by current medications, but often at the expense of 
hypoglycaemia and weight gain. The glucose-dependent stimulation of insulin secretion, the reduction in appetite and 
the improvement in β-cell function with glucagon-like peptide-1 (GLP-1), suggest that incretin-based therapies could 
be an attractive pharmacological target for treatment of type 2 diabetes.
Encouraging results with liraglutide from clinical pharmacology trials and phase 2 trials led to a well-designed, 
comprehensive, phase 3 clinical programme comprising six large randomised controlled trials – The Liraglutide Effect 
and Action on Diabetes (LEAD) programme. The purpose of the LEAD programme was to investigate the clinical efficacy 
and safety of liraglutide as monotherapy or in combination with commonly used treatments in patients with type 2 
diabetes. The application of liraglutide across the continuum of progression of type 2 diabetes was thoroughly evaluated 
in the LEAD trials. Overall, the LEAD programme demonstrated that once-daily liraglutide improved glycaemic control, 
decreased body weight with minimal risk of hypoglycaemia and was well tolerated in patients with type 2 diabetes. It 
also showed that liraglutide reduced systolic blood pressure (SBP) and promoted β-cell function.
Liraglutide is a novel drug that can address the current unmet medical needs in the early treatment of diabetes, both 
as a monotherapy and as an add-on therapy to conventional type 2 diabetes therapies. 
16  © SUPPLEMENT TO JAPI • JUNE 2010 • VOL. 58
In a pre-clinical study with rats, six weeks’ subcutaneous 
administration of liraglutide significantly increased β-cell mass 
with a tendency of increased β-cell proliferation.12
Moreover, along with the positive effects on β cells, Bock et 
al. established that liraglutide had long-term beneficial effects 
on eating behaviour and reduced weight in diabetic rats.13 This 
observation was in agreement with another pre-clinical study 
in obese mini-pigs, where liraglutide treatment reduced the 
weight significantly. A dose-dependent trend was noted with 
liraglutide treatment.14
Animal data also suggest that liraglutide has cardioprotective 
effects. Noyan-Ashraf et al. investigated the pathophysiology 
and outcome of coronary artery occlusion in normal and diabetic 
mice pre-treated with liraglutide. The preliminary findings of 
this study demonstrated that pre-treatment with liraglutide 
improved cardiomyocyte survival and cardiac function after 
induction of experimental myocardial infarction. The beneficial 
effects were independent of effects on body weight or blood 
glucose.15
The actions of GLP-1 are mediated by the GLP-1 receptor, 
which is expressed in many types of cells, including thyroid 
C-cells. Calcitonin which is produced by the C-cells is a classical 
marker for C-cells activation and increased C-cell mass. Knudsen 
et al. investigated the effect of GLP-1 receptor activation in 
C-cells with different GLP-1 analogues (including liraglutide 
and exenatide) in rodents and non-human primates in vitro and 
in vivo.10 The study showed that the GLP-1 analogues stimulated 
calcitonin release, up-regulation of calcitonin gene expression 
and subsequently C-cell hyperplasia in rats and, to a lesser 
extent, mice. In contrast, the GLP-1 analogues did not increase 
calcitonin levels and C-cell hyperplasia were not detected in 
non-human primates even after 20 months of treatment with 
liraglutide (at >60 times human exposure). It could be due to 
low GLP-1 receptor expression in primates’ thyroid C-cells 
compared to rodents, which the study also showed. The results 
were consistent with results obtained from nine clinical trials in 
patients with type 2 diabetes who were exposed to liraglutide 
up to 2 years. Knudsen et al. concluded that there is a difference 
between rodents and primates in thyroid C-cell responsiveness 
to GLP-1 analogues.10
The US FDA has concluded that the risk of carcinomas 
in humans is low, since the incidence in rodents was only 
statistically significant at drug exposure levels many times higher 
than recommended human dose, and it did not affect overall 
survival rates.16 To further explore possible associations between 
medullary thyroid cancer and liraglutide use, the FDA suggested 
the establishment of a cancer registry to monitor the annual 
incidence of medullary thyroid cancer over the next 15 years.16
Overview of Phase 2 and Phase 3 Trials
A 14-week, double-blind, randomised and placebo-controlled 
phase 2 trial investigated the effects of once-daily liraglutide 
at three dosages (0.65 mg, 1.25 mg or 1.90 mg) in patients with 
type 2 diabetes, who had not maintained good glycaemic control 
with diet or an OAD. It showed that liraglutide monotherapy 
resulted in a good glycaemic control without causing any major 
or minor hypoglycaemic episodes. Liraglutide 1.90 mg reduced 
glycated haemoglobin A1c (HbA1c) by 1.74% compared to placebo. 
Approximately 50% of the patients treated with 1.25 mg or 1.90 mg 
achieved the American Diabetes Association (ADA) target for post-
prandial control (≤10 mmol/l).The fasting plasma glucose (FPG) 
levels were significantly decreased versus placebo in patients who 
received the two highest doses of liraglutide. A significant dose-
dependent decrease in body weight (a maximum decrease of 3 kg 
with 1.90 mg) was found in this trial.17
The encouraging results from phase 2 trials with liraglutide 
paved the way for larger-scale phase 3 trials. The Liraglutide Effect 
and Action on Diabetes (LEAD) programme comprised six large 
randomised, controlled phase 3 trials. More than 4000 patients 
were recruited from more than 600 sites in 40 countries, of which 
approximately 2700 received liraglutide administration.  The 
LEAD programme investigated liraglutide as monotherapy or in 
combination with one or more OADs in patients with type 2 diabetes 
who failed to achieve good glycaemic control with their pre-trial 
therapeutic regimens. The purpose of the LEAD trials design was 
to evaluate the application of liraglutide across the continuum of 
progression of type 2 diabetes and compare it with commonly used 
treatments (sulfonylurea [SU], rosiglitazone, insulin glargine and 
Table 1 : LEAD trial designs
Trial LEAD 3 LEAD 2 LEAD 1 LEAD 4 LEAD 5 LEAD 6
Overall description Effect of liraglutide 
in monotherapy
Effect of liraglutide 
in combination with 
metformin
Effect of liraglutide 
in combination with 
glimepiride
Effect of liraglutide 
in combination 
with metformin and 
rosiglitazone
Effect of liraglutide 
in combination 
with metformin and 
glimepiride
Effect of liraglutide 
in combination 
with metformin, 
glimepiride or both
Comparator arms Glimepiride + 
placebo
Metformin + 
placebo
Metformin + 
glimepiride
Glimepiride + 
placebo
Glimepiride + 
rosiglitazone 
Metformin + 
rosiglitazone + 
placebo
Metformin + 
glimepiride + 
placebo
Metformin + 
glimepiride + 
insulin glargine
Metformin and/
or + glimepiride + 
exenatide
Background 
medication
None Metformin Glimepiride Metformin + 
rosiglitazone
Metformin + 
glimepiride
Metformin + 
glimepiride
Overall inclusion 
criteria
Patients with T2DM 
treated with diet/
exercise or OAD
Patients with T2DM 
treated with OADs
Patients with T2DM 
treated with OADs
Patients with T2DM 
treated with OADs
Patients with T2DM 
treated with OADs
Patients with T2DM 
treated with OADs
Patients (N) 746 1091 1041 533 581 464
Primary endpoint HbA1c
(52 weeks) 
HbA1c (26weeks) HbA1c
(26 weeks)
HbA1c
(26 weeks)
HbA1c
(26 weeks)
HbA1c
(26 weeks) with 
14-week extension)
Clinicaltrials.gov 
identifier
NCT00294723 NCT00318461 NCT00318422 NCT00333151 NCT00331851 NCT00518882
HbA1c: glycated haemoglobin A1c; LEAD: Liraglutide Effect and Action in Diabetes; OAD: oral antidiabetic drug; T2DM: type 2 diabetes mellitus.
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exenatide) for type 2 diabetes (Table 1).1,4,5,18,19,20
Data from the different LEAD trials consistently showed that 
liraglutide improved clinical outcomes in terms of glycaemic 
control, body weight and SBP when compared with various 
comparators. In general, the LEAD trials illustrated that liraglutide 
(1.2 mg or 1.8 mg) reduced HbA1c by 1.1-1.5%, induced weight 
loss of 1.0-3.2 kg, decreased blood pressure by 2.1-6.7 mmHg, 
and reduced the cardiovascular risk biomarkers.1,4,5,18,19,20 It was 
also demonstrated that liraglutide had a positive effect on β-cell 
function. However, additional and long-term future studies are 
needed to evaluate whether liraglutide delays the progression of 
type 2 diabetes.1,4,5,18,19,20
Liraglutide was well tolerated in patients participating in 
all LEAD trials. Gastrointestinal disorders, mainly nausea and 
diarrhea, were the most common reported adverse events. However, 
the majority of these events were reported as mild and rarely 
resulted in discontinuation of therapy. Furthermore, the highest 
frequency of the gastrointestinal disorders was seen during the 
initiation of therapy, and therefore transient.1,4,5,18,19,20
In LEAD trials, treatment with liraglutide also presented a lower 
risk of hypoglycaemia. This finding was expected, since liraglutide 
stimulates insulin secretion in a glucose-dependent manner and has 
no effect on glucagon secretion when plasma glucose is low.1,4,5,18,19,20
Calcitonin concentrations were also monitored in order to 
assess any effect of GLP-1 analogues on C cells. All LEAD trials 
demonstrated no safety concern in terms of C-cell proliferation 
in patients treated with once-daily liraglutide. In the controlled 
clinical trials, increases in calcitonin levels occurred in a slightly 
higher percentage of the patients treated with liraglutide than in 
control patients; Increased calcitonin levels with liraglutide were 
shifts from below to slightly above the assay’s detection limit (0.7 
ng per liter) and the levels were still within normal ranges.10,16 In 
longer term studies, there were no treatment related differences in 
calcitonin levels between liraglutide and control groups.10
Sitagliptin is an oral DPP-4 inhibitor, which is another class of 
incretin-based therapy that has been developed for the treatment 
of type 2 diabetes. Compared to GLP-1 analogues that increase 
GLP-1 action, DPP-4 inhibitors prevent native GLP-1 from rapid 
degradation by the DPP-4 enzyme. Thereby, DPP-4 inhibitors work 
indirectly to increase endogenous GLP-1 levels.
A phase 3 trial was designed to directly compare liraglutide 
and sitagliptin, when added to metformin therapy, and thereby 
address differences between the two treatments. This randomised, 
open-label, three-armed, parallel-group trial was conducted using 
665 patients with type 2 diabetes who were assigned to once-daily 
liraglutide 1.2 mg, liraglutide 1.8 mg or 100 mg/day sitagliptin (all 
added on to 1500 mg/day metformin) for a period of 26 weeks. The 
findings of this trial illustrated: 1) better glycaemic control was 
achieved with liraglutide 1.2 mg or 1.8 mg/day than sitagliptin 
100 mg/day; 2) more patients treated with liraglutide achieved the 
ADA target for good glycaemic control than sitagliptin; 3) reduction 
in body weight from baseline to end of treatment was observed 
with all treatments; however, more pronounced weight reduction 
was associated with liraglutide administration; 4) gastrointestinal 
disorders were more frequently reported as adverse events in 
patients treated with liraglutide, but were transient and 5) all 
treatments were associated with low risk of hypoglycaemia.21
Liraglutide has been approved as Victoza in India, to be used 
in the early treatment of type 2 diabetes either as monotherapy or in 
combination therapy with other antidiabetic agents (metformin, SUs 
or thiazolidinediones [TZDs]). Liraglutide can be taken independent 
of meals,20 and the injection timing can be modified during the 
day without the need for dose adjustment.18 This provides the 
maximum treatment flexibility to those diabetic patients with a 
very busy lifestyle.
Conclusions
Liraglutide is a novel GLP-1 analogue developed for the treatment of 
type 2 diabetes as mono- or combination therapy. It possesses additional 
advantages to its existing blood glucose–lowering effect, such as reducing 
body weight and SBP with minimal risk of hypoglycaemia in comparison 
with currently available anti-diabetes treatments. Liraglutide also 
improves the β-cell function. It has been widely documented in clinical 
trials that liraglutide is safe and can be well tolerated in patients with 
type 2 diabetes. It is reasonable to believe that current unmet medical 
needs in terms of attaining optimal diabetes management can well be 
addressed with liraglutide.
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